Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.
about
Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practiceBaseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial.Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia.Clinical implications of pharmacogenomics of statin treatment.Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease.Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.Determination of key intermediates in cholesterol and bile acid biosynthesis by stable isotope dilution mass spectrometry.HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.Inhibition of cholesterol absorption: targeting the intestine.Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey.Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.The detection of heterozygous familial hypercholesterolemia in Ireland.Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected].Sleight of hand in trial design: average behaviour is not average, not all new information is really new.Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
P2860
Q26828401-A1FC6E0B-3CF2-4798-A4BB-3A17A94CD453Q33741212-52C2EC20-D77F-41F9-8A56-E109CD1F3A4BQ35941122-95A4A473-F6AC-4974-A94D-63BA42B53A83Q36426816-3F833C53-FFD2-423E-8216-44B21A45A4ECQ37211743-86A0DDDB-0601-45B3-8114-C97AE9AA466DQ37293985-B3CB9C33-4098-4F68-B346-759FF64985CAQ37474724-17522606-4853-4B3E-8D50-10138433C89EQ37553945-71E7E99C-77B9-44BB-8565-3848F46B8FC5Q37608527-58A9E252-A5AF-4034-856E-C6F0AADCE7CFQ38038125-168BBC6B-3A3A-458A-BD92-BFBB61DE01FFQ39229652-200FD367-D4EB-4096-A8C6-565454603DA3Q43237527-27FDEC71-36B7-44DD-8709-95399C4CFA41Q43718154-EBC42CA8-6551-4243-B93B-63C9743ACDF4Q44256218-AB41D4CA-6A78-480F-8C11-034C5E8BECD6Q46067083-B1BDF029-F85D-4091-BB2C-CEAFCE3866CEQ46447099-F542651F-4455-4ED1-AC75-A6EE0BF0689B
P2860
Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Determinants of variable respo ...... familial hypercholesterolemia.
@en
Determinants of variable respo ...... familial hypercholesterolemia.
@nl
type
label
Determinants of variable respo ...... familial hypercholesterolemia.
@en
Determinants of variable respo ...... familial hypercholesterolemia.
@nl
prefLabel
Determinants of variable respo ...... familial hypercholesterolemia.
@en
Determinants of variable respo ...... familial hypercholesterolemia.
@nl
P2093
P356
P1476
Determinants of variable respo ...... familial hypercholesterolemia.
@en
P2093
Naoumova RP
Neuwirth CK
O'Neill FH
Thompson GR
P304
P356
10.1161/01.ATV.21.5.832
P407
P577
2001-05-01T00:00:00Z